Dupuytren’s Disease Market (2026 - 2033)

Dupuytren’s Disease Market Summary

The global dupuytren’s disease market size was valued at USD 4.7 billion in 2025 and is projected to grow from USD 4.9 billion in 2026 to USD 6.7 billion by 2033, at a CAGR of 4.6% from 2026 to 2033. Europe dominated the market, accounting for a revenue share of 20.0% in 2025. The projected market growth can be attributed to the increasing prevalence and advancements in medical research & technology.

As the market expands, it presents opportunities for stakeholders to meet patients' evolving needs and improve disease management outcomes. The Journal of Hand Surgery emphasizes the importance of developing additional nonsurgical approaches for treating dupuytren's disease, fostering ongoing discussions among hand surgeons about novel therapies and modalities. This review article explores potential treatment options that aim to mitigate the risks associated with invasive treatments and minimize the likelihood of recurrence, ultimately benefiting both patients and healthcare providers.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The market is experiencing significant growth driven by the increasing prevalence of the disease. This has led to increased investment in research and development by pharmaceutical companies and medical device manufacturers to meet demand for effective management strategies. In addition, a 2021 population survey in the U.S. found that up to 7% of the population experiences clinical symptoms, with more than one-third reporting that dupuytren’s contractures affect daily function.

These findings highlight the growing need for accessible and effective treatments. The market holds promising opportunities due to increasing research and development activities and the emergence of new markets. This, combined with the high unmet need for treatments and advancements in healthcare technology, creates a positive market outlook. Notably, the positive results from 180 Therapeutics' Phase 2a clinical trial of anti-TNF therapy in dupuytren’s disease mark a significant milestone. These results highlight the potential breakthrough in managing the condition and the effectiveness of anti-TNF therapy as a viable approach. This opens avenues for further research, development, and exploration of the therapy, potentially revolutionizing the treatment landscape and addressing patients' unmet needs.

Stakeholders in the healthcare industry now have an opportunity to contribute to improving treatment options and enhancing overall disease management, ultimately leading to better patient outcomes worldwide. The market is witnessing increased collaborations and partnerships among key players, leading to expanded product portfolios and innovative advancements. For instance, in October 2020, Endo International's acquisition of Bispecific Technologies Corp. is expected to enhance production and expand the treatment options for dupuytren’s disease. These collaborations enable comprehensive care measures, diagnostic techniques, and diverse treatment options, thereby addressing patients' unmet needs and driving market growth. Such collaborative efforts are crucial in advancing industry and ultimately benefiting patients globally.

Market Dynamics

Analyst Perspective

The dupuytren’s disease industry is being shaped by the growing focus on treatments that can improve patient outcomes while reducing recovery time and the need for invasive procedures. As patients and healthcare providers seek more convenient treatment options, demand is likely to favor therapies that offer effective symptom management with minimal disruption to daily life. Companies with strong clinical evidence, specialized expertise, and established relationships with healthcare providers are expected to maintain a competitive advantage. Over time, treatment effectiveness and patient experience will increasingly shape market success.

Disease Type Insights

The type II segment led the market with the largest revenue share of over 60.0% in 2025. Type II dupuytren’s, characterized by involvement of the palmar fascia and digital cords resulting in finger flexion deformities, is projected to be the leading segment in the market. Recent comprehensive research on the worldwide prevalence of the disease indicates that type II accounts for a substantial proportion of diagnosed cases, underscoring its higher prevalence and impact. For instance, a Study in molecular pathology in the International Journal of Molecular Sciences found that the actively cord-forming stage (type II) accounts for the majority of patients presenting for clinical care. It is simply because most patients are not seeking care in the early stage, as it is asymptomatic.

This dominance underscores the crucial need for effective treatment options and management strategies to address the complexities associated with finger deformities. As a result, pharmaceutical companies and medical device manufacturers are increasingly focusing on developing innovative therapies and interventions specifically targeting type II Dupuytren’s disease to meet the growing demands of the patient population.

Type Insights

The treatment segment led the market with the largest revenue share of over 75.0% in 2025 and is expected to grow at the fastest CAGR over the forecast period, driven by the growing focus on developing effective treatments to manage the disease and improve patients' well-being. Pharmaceutical companies and medical device manufacturers have been actively engaged in research and development activities to introduce innovative treatment approaches. For instance, in June 2023, Endo International Plc announced the enrollment of the first patient in the GRASP-DC (Generating Real-world Ambispective Data to Study Participant Treatment Outcomes for Dupuytren's Contracture) study. It is a registry of 1,000 patients with Dupuytren's disease.

The market has grown as medical technology and surgical methods have improved, offering a wide range of treatment options. These options include non-invasive therapies and surgical procedures that enable healthcare professionals to tailor treatment strategies to each patient's specific needs. In addition, a growing understanding of the value of early diagnosis and intervention among patients and healthcare professionals can be linked to the domination of the treatment segment. The market is anticipated to grow due to industry efforts to meet patient demand, continued research & development, and rising awareness.

End-use Insights

The hospital segment led the market with the largest revenue share of more than 60.0% in 2025, driven by hospitals' role as comprehensive healthcare facilities offering specialized care and treatment options. With dedicated hand surgery and rehabilitation departments, hospitals provide holistic care to patients. In addition, hospitals’ advanced infrastructure and state-of-the-art facilities, including specialized operating rooms, enable them to perform intricate procedures, giving them a competitive edge. An example of this dominance is the establishment of specialized Dupuytren’s disease centers within renowned hospitals. These centers cater specifically to patients with this condition, offering centralized support & comprehensive care from diagnosis through treatment and rehabilitation.

The clinics segment is expected to grow at a significant CAGR over the forecast period, as clinics offering specialized care for Dupuytren's disease attract patients seeking targeted management with shorter waiting times and flexible scheduling. Easy access to minimally invasive procedures in clinics offers less-disruptive options and a quicker recovery. The establishment of specialized Dupuytren’s disease clinics in urban areas addresses comprehensive patient needs, driving the segment's growth and meeting demand for personalized care and specialized expertise.

Regional Insights

Europe dominated the global dupuytren’s disease market with the largest revenue share of more than 40.0% in 2025, attributed to several key factors, including the higher prevalence of the disease, well-established healthcare systems with advanced infrastructure, and strong research & development initiatives. The active participation of industry players and pharmaceutical companies further strengthens Europe's position by driving innovation and facilitating the introduction of advanced therapies. For instance, the enrollment initiative by 180 Life Sciences for their frozen shoulder treatment trial represents a significant research breakthrough with potential benefits for both Dupuytren’s disease and frozen shoulder patients. Furthermore, the recent approval of Xiapex by Swedish Orphan Biovitrum AB (publ) for the treatment of Dupuytren's contracture and Peyronie's disease solidifies Europe's leadership in addressing the healthcare needs of individuals affected by these conditions.

To learn more about this report, Download Free Sample Report

Asia Pacific Dupuytren’s Disease Market Trends

The dupuytren’s disease market in the Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. The region's rapid growth can be attributed to factors such as increased awareness, improved healthcare infrastructure, and advancements in treatment options. The rising awareness of the disease in the region has led to higher diagnosis rates and a greater demand for effective therapies & specialized care. Moreover, the Asia Pacific has witnessed significant advancements in medical technology, including the introduction of collagenase injection therapy, which offers patients a minimally invasive alternative to surgery and has gained popularity in countries such as Japan and South Korea. For instance, in August 2024, a report of 85 clinical studies published by the National Institutes of Health (NIH) contradicts the long-held assumption that Dupuytren's contracture is primarily a Western or Caucasian disease. The true prevalence rate of the disease across prominent Asian populations, specifically in Japan, South Korea, and China, stands at 15.3%

Key Dupuytren’s Disease Company Insights

The market is growing significantly due to rising awareness, advances in treatment, and a larger patient population. This creates opportunities for major players to capitalize on by offering effective therapies and specialized care. Market participants are actively pursuing strategic initiatives such as mergers, acquisitions, and collaborations to enhance their market share and meet the rising demand for disease treatment.

Key Dupuytren’s Disease Companies

The following key companies have been profiled for this study on the Dupuytren’s disease market.

• Bayer AG

• Novartis AG

• Pfizer Inc.

• Nantong Jinghua Pharmaceutical Co., Ltd.

• Actiza Pharmaceutical Private Limited

• Endo International plc

• Bristol-Meyers Squibb Company

• Spear Pharmaceuticals

• GSK plc

• AstraZeneca

• Hikma Pharmaceuticals PLC

• LEO Pharma A/S

• Fresenius Kabi AG

Recent Developments

• In November 2024, John Elway partnered with Endo Inc. to improve awareness for early detection and treatment of Dupuytren's contracture. They are also educating about the use of XIAFLEX (collagenase clostridium histolyticum) as a nonsurgical treatment for the disease.

• In July 2024, Connext completed the successful first administration of CNT201, its treatment for Dupuytren's contracture, in patients. They secured IND approval for their Phase 1/2 clinical trials from the U.S. FDA and completed the Clinical Trial Notification (CTN) procedure in Australia. The trial involved a single administration of four escalating dose levels to patients with Dupuytren's contracture, followed by a 4-week assessment period to evaluate safety, tolerability, efficacy, pharmacokinetics, and immunogenicity.

Global Dupuytren’s Disease Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dupuytren’s disease market report based on the disease type, type, end use, and region:

To learn more about this report, Download Free Sample Report

• Disease Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Type I

  • Type II

  • Type III

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Diagnosis

    • Physical Examination

    • X-ray

  • Treatment

    • Surgery

    • Radiation Therapy

    • Needle Aponeurotomy

    • Steroid Shot

    • Enzyme Injection

    • Occupational Therapy

    • Others

• End-use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospitals

  • Clinics

  • Academic & Research Institute

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE